GlassScriptPhysician profile
Megan E Strausbaugh
NPI 1952846016
$1,559.22
in general payments reported to CMS, 2019-2025
28 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $282 · 2023: $375 · 2024: $367 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.08 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $206.52 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.29 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $138.63 | 2021-2024 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $95.13 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $92.05 | 2021-2025 | Ubrelvy, Qulipta |
| Preventric Diagnostics, INC. | $77.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.34 | 2021-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $68.98 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $43.54 | 2023 | Shingrix, Arexvy |
| Neurocrine Biosciences, INC. | $39.00 | 2024-2025 | Ingrezza |
| Eisai INC. | $35.62 | 2021 | |
| Phathom Pharmaceuticals, INC. | $33.65 | 2023-2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $28.95 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $28.93 | 2023-2024 | Austedo Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.42 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $25.33 | 2021 | |
| Medtronic, INC. | $23.52 | 2024 | Intellis Adaptivestim |
| Seqirus USA INC | $18.93 | 2024 | Flucelvax, Fluad |
| Ironshore Pharmaceuticals INC. | $16.66 | 2023 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.38 | 2023 | |
| Corcept Therapeutics | $14.55 | 2025 | Korlym |
| Astellas Pharma US INC | $14.48 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $14.14 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.92 | 2022 | |
| Gilead Sciences, INC. | $13.32 | 2023 | |
| Pfizer INC. | $13.25 | 2023 | |
| Electromed, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Strausbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.